Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities
Over 77% Of All Shares Voted; Proposals Received Overwhelming Positive Votes
Annual Meeting Results
There was an exceptionally strong vote turnout at the 2023 Annual Meeting, with 961.7 million votes cast out of the total 1.2 billion shares outstanding as of the record date, comprising over 77% of all common and preferred shares outstanding. This vote turnout repeated the exceptional turnout at the 2022 Annual Meeting, where 841 million votes were cast comprising 78% of the total shares that were then outstanding.
There were 5 Proposals for shareholders to decide at the 2023 Annual Meeting, and all of them were approved by shareholders with overwhelming margins. The votes were as follows:
Proposal 1: Re-Election of Class I Directors for a new 3-year term
- Dr.
Alton Boynton was re-elected. 94.04% of the votes cast were in favor. - Ambassador
Cofer Black was re-elected. 93.01% of the votes cast were in favor.
Proposal 2: Ratification of Appointment of Independent Auditor –
- The appointment was ratified. 92.73% of the votes cast were in favor.
Proposal 3: Ratification of Stock Options awarded to Management in 2020.
- The Option awards were ratified. 88.13% of the votes cast were in favor.
Proposal 4: Ratification of Stock Options Awarded to Non-Executive Directors in 2020.
- The Option awards were ratified. 88.05% of the votes cast were in favor.
Proposal 5: Approval, on an advisory basis, of executive compensation in 2023.
- The compensation was approved on an advisory basis. 87.37% of the votes cast were in favor.
Review of Progress Since Prior Annual Meeting, and Plans and Opportunities Going Forward
During the Annual Meeting, the Company also conducted an informal discussion session that was publicly available by audio link to all interested parties. An audio recording has also been posted on the Company's website and will remain available there through
During the discussion session, the Company reviewed its strong progress since the last Annual Meeting and described its plans and priorities, and its many growth opportunities, going forward. The Company's descriptions of plans and opportunities were subject to standard cautions about forward looking statements and related uncertainties and risks.
"We are excited about the Company's progress on many fronts over the last 18 months, including in regard to the Marketing Authorization Application (MAA) in the
"We are especially grateful for the ongoing strong support from our shareholders, as reflected in the exceptional voting results of the Annual Meeting."
About
Disclaimer
Statements made in this news release that are not historical facts, including statements concerning plans for DCVax are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "design," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those projected in any forward-looking statement. Readers should not rely upon forward-looking statements. There are a number of important factors that could cause actual results to differ materially from those anticipated, including, without limitation, risks related to delays or uncertainties in regulatory processes and decisions, risks related to the Company's ability to achieve timely performance of third parties, risks related to whether the Company's products, including products involving in-licensed intellectual property, will be viewed as demonstrating safety and efficacy, risks relating to funding or implementation of clinical trials, including trials involving in-licensed intellectual property, risks related to the Company's ongoing ability to raise additional capital, and other risks included in the Company's
CONTACTS |
|
|
|
|
|
|
|
|
|
804-513-6758 |
240-234-0059 |
Logo - https://mma.prnewswire.com/media/325355/northwest_biotherapeutics__inc__logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/northwest-biotherapeutics-announces-positive-votes-at-annual-meeting-reviews-strong-progress-and-growth-opportunities-302189074.html